Insider · CIK 0001506916
Jeffrey A Meckler
Files at TVTX (Travere Therapeutics, Inc.), INDP (Indaptus Therapeutics, Inc.). First filing May 6, 2026, latest Sep 11, 2026.
In brief
Jeffrey A Meckler files SEC Form 4 as CEO, director and 10% owner at TVTX (Travere Therapeutics, Inc.), and also at INDP (Indaptus Therapeutics, Inc.). Since May 6, 2026, Jeffrey A Meckler has reported 0 open-market buys worth $0 and 2 open-market sells worth $1.7M, the latest filed on Sep 11, 2026.
A track record needs three past buys with six months of prices behind them; Jeffrey A Meckler has 0, so none is measured yet.
The newest scored trade: sold $1.3M of TVTX on Sep 10, 2026, filed Sep 11, 2026, scored 25 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $1.7M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TVTX: Travere Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Travere Therapeutics, Inc. | $1.3M 20,000 shares | -18% | +196% from low-0% from high | |
| 10Weak | Travere Therapeutics, Inc. | $360k 8,000 shares | -8% | +219% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 10, 2026 | TVTX TRAVERE THERAPEUTICS INC | 20,000 0.02% of outstanding | $1.3M | Sep 10, 2026 | none |
| May 4, 2026 | TVTX TRAVERE THERAPEUTICS, INC. | 8,000 0.01% of outstanding | $360k | May 4, 2026 | none |
Transactions
Every row this insider has filed, 33 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +10,000 | $17.44 | $174k | 101,500 | 33 d ago |
| Sep 10, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +10,000 | $26.52 | $265k | 111,500 | 33 d ago |
| Sep 10, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,700 | $65.39 | $111k | 109,800 | 33 d ago |
| Sep 10, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,200 | $66.15 | $79k | 108,600 | 33 d ago |
| Sep 10, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -14,000 | $67.46 | $944k | 94,600 | 33 d ago |
| Sep 10, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,100 | $68.09 | $211k | 91,500 | 33 d ago |
| Sep 10, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Stock option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | 33 d ago |
| Sep 10, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Stock option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | 33 d ago |
| May 19, 2026 | TVTX Travere Therapeutics, Inc. | AGrant or award Common Stock | +4,000 | $0.00 | $0 | 91,500 | May 21, 2026 |
| May 19, 2026 | TVTX Travere Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +12,000 | $0.00 | $0 | 12,000 | May 21, 2026 |
| May 4, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +8,000 | $16.33 | $131k | 95,500 | May 6, 2026 |
| May 4, 2026 | TVTX Travere Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,000 | $45.00 | $360k | 87,500 | May 6, 2026 |
| May 4, 2026 | TVTX Travere Therapeutics, Inc. | MOption exercise Stock option (right to buy)derivative10b5-1 | -8,000 | $0.00 | $0 | 0 | May 6, 2026 |
| Feb 11, 2026 | INDP Indaptus Therapeutics, Inc. | DDisposition to issuer Warrants (right to buy)derivative | -3,033 | - | - | 0 | Feb 13, 2026 |
| Feb 11, 2026 | INDP Indaptus Therapeutics, Inc. | AGrant or award Warrants (right to buy)derivative | +3,033 | - | - | 3,033 | Feb 13, 2026 |
| Feb 11, 2026 | INDP Indaptus Therapeutics, Inc. | DDisposition to issuer Warrants (right to buy)derivative | -1,519 | - | - | 0 | Feb 13, 2026 |
| Feb 11, 2026 | INDP Indaptus Therapeutics, Inc. | AGrant or award Warrants (right to buy)derivative | +1,519 | - | - | 1,519 | Feb 13, 2026 |
| Feb 11, 2026 | INDP Indaptus Therapeutics, Inc. | DDisposition to issuer Warrants (right to buy)derivative | -12,136 | - | - | 0 | Feb 13, 2026 |
| Feb 11, 2026 | INDP Indaptus Therapeutics, Inc. | AGrant or award Warrants (right to buy)derivative | +12,136 | - | - | 12,136 | Feb 13, 2026 |
| Dec 22, 2025 | INDP Indaptus Therapeutics, Inc. | AGrant or award Common Stock | +216,617 | $2.03 | $440k | 229,929 | Dec 29, 2025 |
| Jul 27, 2025 | INDP Indaptus Therapeutics, Inc. | AGrant or award Common Stock | +6,068 | $8.30 | $50k | 13,312 | Jul 29, 2025 |
| Jul 27, 2025 | INDP Indaptus Therapeutics, Inc. | AGrant or award Common Stock Warrantsderivative | +12,136 | $8.30 | $101k | 16,688 | Jul 29, 2025 |
| May 15, 2025 | TVTX Travere Therapeutics, Inc. | AGrant or award Common Stock | +6,500 | $0.00 | $0 | 87,500 | May 16, 2025 |
| May 15, 2025 | TVTX Travere Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +19,500 | $0.00 | $0 | 19,500 | May 16, 2025 |
| Apr 10, 2025 | INDP Indaptus Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -4,750 | $0.04 | $176 | 0 | Apr 11, 2025 |
| Apr 10, 2025 | INDP Indaptus Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -3,750 | $0.04 | $139 | 0 | Apr 11, 2025 |
| Apr 10, 2025 | INDP Indaptus Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -813 | $0.04 | $30 | 0 | Apr 11, 2025 |
| Apr 10, 2025 | INDP Indaptus Therapeutics, Inc. | DDisposition to issuer sStock Option (right to buy)derivative | -1,500 | $0.04 | $56 | 0 | Apr 11, 2025 |
| Apr 10, 2025 | INDP Indaptus Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -1,563 | $0.04 | $58 | 0 | Apr 11, 2025 |
| Apr 10, 2025 | INDP Indaptus Therapeutics, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -1,250 | $0.04 | $46 | 0 | Apr 11, 2025 |
| Nov 25, 2024 | INDP Indaptus Therapeutics, Inc. | AGrant or award Common stock | +42,553 | $1.18 | $50k | 202,859 | Nov 26, 2024 |
| Nov 25, 2024 | INDP Indaptus Therapeutics, Inc. | AGrant or award Common Stock Warrantsderivative | +42,553 | $1.18 | $50k | 42,553 | Nov 26, 2024 |
| Jan 22, 2024 | INDP Indaptus Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 23, 2024 |
Questions about Jeffrey A Meckler
Answered from the filings on this page, as of the latest one.
Is Jeffrey A Meckler buying or selling?
In the last 12 months Jeffrey A Meckler reported 0 open-market buys worth $0 and 2 open-market sells worth $1.7M on SEC Form 4; the latest was sold $1.3M of TVTX on Sep 10, 2026. Grants, option exercises and tax withholding are not counted.
How did Jeffrey A Meckler's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey A Meckler has 0.
Where does Jeffrey A Meckler file Form 4?
Jeffrey A Meckler has filed Form 4 at TVTX (Travere Therapeutics, Inc.); INDP (Indaptus Therapeutics, Inc.) as CEO and Director. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.